Andrew Bryant's research while affiliated with Newcastle University and other places

Publications (12)

Preprint
Rapid Response to BMJ Evidence-Based Medicine re Popp et al., Letter to Editor, DOI: 10.1136/bmjebm-2021-111791. Rapid Responses appear as tabs to the original Letter but do not acquire DOI references. This posting provides a DOI to the text of the Rapid Response and a clear text with errors of formatting in the journal version repaired.
Preprint
Full-text available
A review of a recent Cochrane Review of ivermectin in Covid-19
Preprint
Rapid Response submitted to BMJ Evidence-Based Medicine
Article
Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis...
Preprint
Full-text available
Background Re-purposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with anti-viral and anti-inflammatory properties, has now been tested in numerous clinical trials.Areas of uncertainty We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemo-prophylaxis, a...
Preprint
Background Re-purposed medicines may have role in combating the SARS-CoV-2 virus. The antiparasitic medicine ivermectin, which has anti-viral and anti-inflammatory properties, has been tested in numerous clinical trials with promising results.Methods We assessed the efficacy of ivermectin treatment and/or prophylaxis among people with, or at high r...
Preprint
Full-text available
Background Re-purposed medicines may have role in combating the SARS-CoV-2 virus. The antiparasitic medicine ivermectin, which has anti-viral and anti-inflammatory properties, has been tested in numerous clinical trials with promising results. Methods We assessed the efficacy of ivermectin treatment and/or prophylaxis among people with, or at high...
Article
Background: Multiple studies have identified the prognostic relevance of extent of resection in the management of glioma. Different intraoperative technologies have emerged in recent years with unknown comparative efficacy in optimising extent of resection. One previous Cochrane Review provided low- to very low-certainty evidence in single trial a...
Article
Full-text available
Background: In the UK, most people with dementia die in the community and they often receive poorer end-of-life care than people with cancer. Objective: The overall aim of this programme was to support professionals to deliver good-quality, community-based care towards, and at, the end of life for people living with dementia and their families....

Citations

... On September 3, a rapid response by Bryant et al. to Popp et al. [177] stated that their Bryant et al. metaanalysis was a non-commissioned research paper that strictly followed PRISMA systematic review guidelines, and that Popp et al. itself contained several misleading items, including using death instead of infection for the prophylaxis outcome, specifying outcome measures not found in the included trials but ignoring the outcome measures found in the trials, subsequently stating that they found 'no data' [251]. The authors concluded that in a pandemic context, the benefits of ivermectin almost certainly outweighed any risks. ...
... On April 14, an editorial by Meyerowitz-Katz et al. in the BMJ said that there was no better example of divergence from the rigorous standards to which medical research should adhere to than the research into ivermectin for COVID-19 [166]. As examples, the article mentioned the meta-analysis by Bryant et a. [167], the meta-analysis by Hill et al. [19], and a preprint by Merino et al. [49]. It said flawed research meant that ivermectin's safety and efficacy was still unknown. ...
... 594 Ivermectin is a natural and broad-spectrum anti-infective agent found in Streptomyces avermitilis, and it can inhibit the replication of HIV-1, Newcastle disease virus and dengue virus. 597 Research indicated it exerts inhibitory effects on SARS-CoV-2 replication in the early stages of infection. Ivermectin has recently been reported as a potent inhibitor of SARS-CoV-2 infection, with an excellent ability to reduce viral RNA levels in Vero-hSLAM cells. ...
... On May 17, a preprint by Bryant et al. provided an updated version of the BIRD group's ivermectin metaanalysis [339]. Twenty-four RCTs involving 3,406 participants met review inclusion. ...
... 4 Attributable to the global problems and the rapid spread of this disease, there are research groups dedicated to testing drugs that contribute to prevent and improve the prognosis of the disease (e.g. Ivermectin, 5 Vitamin D, 6 and Hydroxychloroquine 7 ). However, the global crisis continues, and it is necessary to test other substances that could effectively prevent the spread of SARS-CoV-2 and develop COVID19. ...
... Such a repurposed drug should preferably treat most of the hallmarks of cardiovascular disease. We investigated such a drug namely, ivermectin (150)(151)(152)(153)(154)(155). Although ivermectin use is still controversial as a drug against Covid-19, studies over nearly three decades before Covid-19, has shown to reduce four of the five hallmarks of cardiovascular disease. ...
... Because of the presence of GSCs, it requires complete destruction of the tumor, even a miniscule amount of residual tumor can lead to fatal recurrence [46]. Recently, intraoperative imaging techniques to maximize extent of resection have contributed considerably in defining the margins of glioblastoma [47,48]. However, radical extirpation of the tumor is not possible due to infiltration of the tumor into the surrounding brain, the role of image-guided surgery in maximizing extent of resection remains uncertain [46]. ...
... Regardless of rates of admission, it is important that hospital and community palliative care services are skilled specifically in care of the person with dementia at end of life. It is also important that end of life care and dementia care are integrated [6], which is unlikely where there are differing commissioning arrangements for services. Knowing the preferred place of death for people with dementia is vital, and the authors draw attention to a further study published in Age and Ageing showing most preferred to die in a care home or home [7]. ...